cc-5013
Indolent Non-Hodgkin's Lymphoma
Gilead SciencesPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Indolent Non-Hodgkin's Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER SecuraBio | Phase 3 | BB |
Bendamustine SecuraBio | Phase 3 | BB |
Zofran SecuraBio | Phase 3 | BB |
BMS-986345 SecuraBio | Phase 3 | CCC |
Idelalisib Gilead Sciences | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →